CSI Market
Sign In | Register

Arbutus Biopharma (ABUS) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ABUS quarterly Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Arbutus Biopharma adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-33.50
Depreciation & amortization0.36
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue-10.43
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability-1.83
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.67
Share-based Compensation6.95
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized0.01
Effect Of Exchange Rate On Foreign Currency Cash Balances-
Warrant Issuance Costs-
Fair Value Option Changes In Fair Value Gain Loss-
Impairment Of Intangible Assets Excluding Goodwill-
Fair Value Option Changes In Fair Value Gain Loss-
Non Cash Royalty Revenue Related To Sale Of Future Royalties-1.48
Non Cash Royalty Expense Related To Sale Of Future Royalties-
Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability-
Restructuring Settlement And Impairment Provisions2.81
Income taxes0.00
Gain (Loss) on Sale of Equity Investments0.00
Accounts Receivable-1.38
Increase (Decrease) in Accounts Payable and Accrued Liabilities-2.11
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.70
Other Working Capital-0.56
Other Noncash Income (Expense)0.00
Other net2.35
Payments for (Proceeds from) Other Operating Activities-2.25
Discontinued operations0.00
Net Cash flow from Operating Activities-39.64
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.36
Payments for (Proceeds from) Investments0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds from Sale of Restricted Investments0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments140.06
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Payments to Acquire Equity Method Investments0.00
Sale of businesses0.00
Accounts payable0.00
Payments for Advance to Affiliate0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities15.58
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock5.54
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-36.33
Fair Value Of Warrants Exercised On A Cashless Basis-
Noncash Financial Or Equity Instrument Consideration Fair Value Of Warrants Exercised-
Capital Expenditures Incurred But Not Yet Paid-
Fair Value of Warrants Exercisedona Cashless Basis-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents36.33
Proceeds From Sale Of Future Royalties Net-
Proceeds From Issuance Of Common Stock Share Purchase Agreement-
Proceeds From Issuance Of Common Stock Open Market Sale Agreement-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities5.72
Effect of exchange rate on cash flow0.01
Discontinued operations0.00
Free Cash Flow-39.27
Total Cash Flow-18.32
4 historic quarters locked

Sign in to unlock the full Arbutus Biopharma cash flow history.

Sign In Create Free Account

About Arbutus Biopharma Corp Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001447028-26-000017

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License